Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,801–1,900 of 3,636
Lu, J., Zhang, H., Chen, B., Yang, Y., Cui, J., Xu, W., Song, L., Yang, H., He, W., Zhang, Y., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003199 · Cited by 7
“…LDL-C and CVD mortality were observed, and the HR point estimates of very low LDL-C were less than 1.00, we failed to observe a significant protective effect on CVD mortality, as indicated in recent clinical trials; [29,30] this may be owing to the limited number of CVD deaths in our cohort.”
ResultInfluentialMonoclonal Anti-PCSK9 Antibodies: Real-World Data
Guidotti, G., Liberati, V., Sorrentino, A., Lotti, E., Crudele, F., Rogolino, A. A., Sammartino, A., Slanzi, M., Gori, A. M., Marcucci, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154543 · Cited by 7
“Indeed, we recorded an overall median reduction of 57.83 ± 24.5% in LDL-C levels after PCSK9mAb initiation, which was maintained throughout the study period [14,15,26].”
BackgroundInfluentialPuri, R., Mehta, V., Bansal, M., Shetty, S., Yusuf, J., Agarwala, R., Vijan, V., Muruganathan, A., TIWASKAR, M. H., Narasingan, S. N., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0614 · Cited by 8
Ábel, T., Benczúr, B., & Csobod, É. C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1458025 · Cited by 8
“The results of human studies on the effect of PCSK9 inhibitors on MASLD are contradictory (91–95).”
BackgroundLamia, T. H., Shah-Riar, P., Khanam, M., Khair, F., Sadat, A., Tania, M. K., Haque, S. M., Saaki, S. S., Ferdausi, A., Naurin, S. A., et al. (2024) · Cureus · doi:10.7759/cureus.71365 · Cited by 11
Cleto, A. S., Schirlo, J. M., Gomes, V. H. O., Beraldo, M. L. J., Neiverth, G. S., Beltrame, M. L., Machozeki, J., & Martins, C. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16091 · Cited by 8
“2,27,28 No studies with cardiovascular outcomes were carried out with inclisiran.”
Junaid, V., Minhas, A. M. K., Inam, M., Hinkamp, C. A., Talha, K. M., Meloche, C., Sheikh, S. S., Khoja, A. A., Krittanawong, C., Vaughan, E. M., et al. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01253-z · Cited by 7
“Reduction of LDL-C after acute myocardial infarction (AMI) improves prognosis and risk for cardiovascular events, and larger reductions in LDL lead to better outcomes [19–21].”
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
“These mAbs have shown benefits in cardiovascular outcome studies [9,10].”
Clonal hematopoiesis of indeterminate potential and cardiovascular diseases: A review
Senguttuvan, N. B., Subramanian, V., Muralidharan, T., Sankaranarayanan, K., Venkatesan, V., & Thanikachalam, S. (2025) · Indian Heart Journal · doi:10.1016/j.ihj.2025.01.006 · Cited by 6
“18 Residual risk is categorized into inflammatory, thrombotic, and metabolic types.”
Minami, Y., Ikari, Y., Harada, M., Suzuki, H., Fukui, K., Ako, J., Akashi, Y. J., Hibi, K., Kamioka, N., Koga, M., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-24-0714 · Cited by 7
Razavi, A. C., Troy, A. L., Patel, J., Mehta, L. S., Spitz, J. A., Lloyd‐Jones, D. M., Whelton, S. P., Johansen, M. C., & Blumenthal, R. S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101724 · Cited by 8
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70122 · Cited by 7
Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors
Balakrishna, A. M., Kaushik, S., Tandalam, S., Monther, N., Ponamgi, S., Alla, V. M., & Patil, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134562 · Cited by 10
Understanding and preventing atherosclerosis: from bench to bedside
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz001 · Cited by 6
Maciejko, J. J., Jamoua, R., & Anne, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00352-6 · Cited by 6
Raal, F. J., Tuomilehto, J. O., Sposito, A. C., Fonseca, F. A. H., Averna, M. R., Farnier, M., Santos, R. D., Ferdinand, K. C., Wright, R. S., Navarese, E. P., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.06.006 · Cited by 7
Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials
Tinahones, F. J., Laufs, U., Cariou, B., Louie, M. J., Yang, J., Thompson, D. E., & Leiter, L. A. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101120 · Cited by 6
Initiating PCSK9 Inhibition in Hospital for ACS
Schwartz, G. G., & CHAITMAN, B. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.039 · Cited by 6
Self-citationVolis, I., Saliba, W., Jaffe, R., Eitan, A., & Zafrir, B. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.04.043 · Cited by 7
Bempedoic acid for the treatment of hypercholesterolemia
Yang, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1782744 · Cited by 6
“lesterolemia PCSK9 inhibitor (evolocumab or alirocumab), administered alone or in combination with statins or ezetimibe, could reduce LDL-C by 50–60%, and non-HDL-C by 40–50% [22].”
BackgroundDavis, L. E., & Pogge, E. K. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00399-6 · Cited by 7
“Furthermore, side effects and efficacy outcomes may vary in the older adult populations as compared to the studied population, which had an average age of approximately 60 years in key clinical trials [6, 7].”
BackgroundResultInfluentialZhou, X., & Yang, Q. (2020) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000067 · Cited by 6
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Egbaria, A., Saliba, W., & Zafrir, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07107-5 · Cited by 6
Therapieempfehlungen bei Fettstoffwechselstörungen: Die neue Leitlinie von 2019
Vogt, A., & Weingärtner, O. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8193 · Cited by 6
“Therapie Durchschnittliche LDL-C-Senkung moderate Dosierung eines Statins 30 % hochdosiertes Statin 50% hohe Dosierung eines Statins + Ezetimib 65% PCSK9-Inhibitor 60 % PCSK9-Inhibitor + hochdosiertes Statin 75% PCSK9-Inhibitor + hochdosiertes Statin + Ezetimib 85% 81Vogt A et al. Therapieempfehlungen bei Fettstoffwec…”
BackgroundInfluentialCurrent Evidence and Future Directions of PCSK9 Inhibition
Xu, J., & Shapiro, M. D. (2021) · US Cardiology Review · doi:10.15420/usc.2020.17 · Cited by 8
Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
van Bruggen, F. H., & Luijendijk, H. J. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00480-y · Cited by 7
“In the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial investigating the clinical outcomes of alirocumab, 16% of cardiovascular deaths were attributed to causes other than MI or stroke [10], and 13% in clinical outcomes trials of statins…”
BackgroundAllen, K. B., Alexander, J. E., Liberman, J. N., & Gabriel, S. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00328-4 · Cited by 7
“, statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors) take several months to years to have a pronounced effect on CV events [35, 36].”
BackgroundCuomo, G., Cioffi, G., Lorenzo, A. D., Iannone, F. P., Cudemo, G., Iannicelli, A. M., Pacileo, M., D’Andrea, A., Vigorito, C., Iannuzzo, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113247 · Cited by 8
“001), which were death from CAD, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization [19].”
Toyota, T., Morimoto, T., Iimuro, S., Fujita, R., Iwata, H., Miyauchi, K., Inoue, T., Nakagawa, Y., Nishihata, Y., Daida, H., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0168 · Cited by 7
Gielen, S., Wienbergen, H., Reibis, R. K., Köenig, W., Weil, J., & Landmesser, U. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00580-2 · Cited by 8
“[10, 11]) nun als Klasse-I A-Empfehlung zwingend empfohlen.”
Review of Recent Laboratory and Experimental Data on Cardiotoxicity of Statins
Chaulin, A. M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110403 · Cited by 7
Catapano, A. L., Vrablík, M., Karpov, Y., Berthou, B., Loy, M., & Baccara‐Dinet, M. T. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221138284 · Cited by 13
“5% of patients with a recent myocardial infarction had heart failure.(21,22) However, in a recent real-world evidence study of acute coronary syndrome, with 97% of participants classified as VHR, the reported rate of heart failure was 35.”
BackgroundLipid lowering therapy in 2022 and beyond - How far we have come
Saseen, J. J., & Virani, S. S. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.008 · Cited by 6
Value of expert opinion in recommending early intensive lipid lowering in patients with ACS
White, H. D. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac136 · Cited by 6
Self-citationThe Societal Impact of Inclisiran in England: Evidence From a Population Health Approach
Ostwald, D. A., Schmitt, M., Peristeris, P., Gerritzen, T., & Durand, A. (2023) · Value in Health · doi:10.1016/j.jval.2023.05.002 · Cited by 6
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
“Further reduction in LDL-c would result in decreasing future cardiovascular events [11,12].”
BackgroundNew Perspectives on Cholesterol and Lipoprotein Metabolism
Geest, B. D., & Mishra, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411298 · Cited by 7
“Fully human monoclonal antibodies directed against PCSK9, namely alirocumab and evolocumab, have been used in the treatment of selected patients with hypercholesterolemia for several years [30,31].”
BackgroundGenetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Kovach, C. P., Mesenbring, E. C., Gupta, P., Glorioso, T. J., Ho, P. M., Waldo, S. W., & Schwartz, G. G. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29066 · Cited by 7
Self-citationAbrahams, T., Fujino, M., Nelson, A. J., & Nicholls, S. J. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001080 · Cited by 8
“These studies have advanced our understanding of benefits from promoting underscoring their impact on cardiovascular events [34,35].”
Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 22
Lipid-Lowering Therapy after Acute Coronary Syndrome in Outpatient Practice—How to Achieve Goal
Rajtar-Salwa, R., Bobrowska, B., Batko, J., Bartuś, S., Dimitrow, P. P., & Krawczyk‐Ożóg, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206579 · Cited by 6
“If the targeted goals cannot be achieved with the highest tolerated dosage of a statin alone, it is recommended that a combination with ezetimibe [13] and the next proprotein convertase subtilisin/kexin type 9 inhibitors be considered [14,15].”
BackgroundModern algorithms for statin therapy
Susekov, A. V. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5594 · Cited by 6
Amin, K. D., Bethel, G., Jackson, L. R., Essien, U. R., & Sloan, C. E. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01180-5 · Cited by 5
“For example, the ODYSSEY and FOURIER trials, which established the efficacy of PCSK9 inhibitors, each enrolled 25% women ( N = 4762/18,924 and N = 6769/27,564, respectively) [76, 77].”
Svensson, M. K. E., James, S. K., Ravn‐Fischer, A., Villa, G., Schalin, L., Cars, T., Gustafsson, S., & Hagström, E. (2024) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v129.9618 · Cited by 9
“…9 (PCSK9) using monoclonal antibodies has been shown to lower LDL-C levels by approximately 60% and to reduce the risk of major ASCVD events across a wide range of different patient populations in clinical trials, when used in monotherapy or in addition to other lipid-lowering therapy (LLT) (4–7).”
BackgroundAlieva, A. S., Usova, E., Звартау, Н. Э., & Shlyakhto, E. V. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5724 · Cited by 9
Szarek, M. J., Reijnders, E., Steg, P. G., Jukema, J. W., Schwertfeger, M., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae110 · Cited by 10
Self-citationAtherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
“Large phase 3 outcome studies showed a significant decrease in LDL-c, which was translated into a significant reduction in adverse clinical outcomes [31,32].”
BackgroundMethodInfluentialHu, D., Qin, D., Kuang, J., Yang, Y., Weng, S., Chen, J., Wu, S., Wang, S., Mao, L., Peng, D., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001592 · Cited by 7
“15,16 Although PCSK9 inhibition with monoclonal antibodies has proven effective and safe in reducing cardiovascular risk, 17 – 19 the general administration of PCSK9 inhibitors in clinical practice remains limited owing to their high cost and inconvenience.”
Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events
Al-Ani, A., Jamil, Y., & Orkaby, A. R. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01139-4 · Cited by 7
“Moreover, a few other large randomized controlled trials have shown effectiveness in reducing cardiovascular events as secondary prevention when using PCSK9 inhibitors [87–89].”
Kim, K., Faruque, S. C., Lam, S., Kulp, D., He, X., Sperling, L. S., & Eapen, D. J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101184 · Cited by 7
Lipid-lowering therapy after acute coronary syndromes: a multinational European survey
Tsaban, G., Vidal-Pérez, R., Krychtiuk, K. A., Ahrens, I., Halvorsen, S., Hassager, C., Huber, K., Schiele, F., Sionís, A., & Claeys, M. J. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001420 · Cited by 6
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 7
Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?
Sabouret, P. F., Farnier, M., & Puymirat, É. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.01.009 · Cited by 9
Should myocardial infarction type 2 be regarded as two separate entities?
Thygesen, K. A., & Jaffe, A. S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz451 · Cited by 6
Page, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
Galiano, M., Hammersen, J. E., Sauerstein, K., Blessing, H., Rümmele, P., Purbojo, A., Schöber, M., Moosmann, J., Raffelsbauer, G., Heibges, A., et al. (2020) · Journal of Clinical Apheresis · doi:10.1002/jca.21772 · Cited by 6
Dyslipidaemias and their treatment in high complexity centres in Colombia
Ruiz, Á. J., Vargas‐Uricoechea, H., Urina‐Triana, M., Román-Gonzaléz, A., Isaza, D., Etayo, E., Quintero, A. E., Molina, D. I., Toro, J. M., Parra, G., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.05.001 · Cited by 6
Shimada, T., Osakada, K., Okabe, K., Shima, Y., Eguchi, H., Habara, S., Tada, T., Taguchi, Y., Ikuta, A., Takamatsu, M., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01696-9 · Cited by 6
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
“PCSK9 inhibitors appear to be well tolerated, as the incidence of adverse effects were similar to placebo apart from injection-site reactions in trials [20,21].”
BackgroundResultInfluentialGroth, N. A., Stone, N. J., & Benziger, C. P. (2020) · Clinical Cardiology · doi:10.1002/clc.23521 · Cited by 7
Cimaglia, P., Paola, L. D., Carone, A., Scavone, G., Manfrini, M., Brogneri, S., Tenti, E., Pavasini, R., Bernucci, D., Passarini, G., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.595701 · Cited by 7
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab in ODYSSEY OUTCOME (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated R…”
BackgroundTemporal trends of lipid control in very high cardiovascular risk patients
Araújo, P. M., Nunes, A., Torres, S., Resende, C. X., Leite, S., Rodrigues, J., Amorim, S., Martins, E., Campelo, M., & Maciel, M. J. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repc.2020.10.018 · Cited by 7
ALERT-LDL: adherence to guidelines in the treatment of patients with dyslipidemia
Bosso, G., Luca, M. D., Alma, G., Carbone, V., Ferrara, F., Fimiani, B., Guarnaccia, F., Iandolo, A., Murolo, S., Olivares, M., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02809-6 · Cited by 6
Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail
Fiolet, A. T. L., Opstal, T. S. J., Silvis, M. J. M., Cornel, J. H., & Mosterd, A. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01605-3 · Cited by 8
Pinto, L. C. S., Mello, A. P. D. Q., Izar, M. C. D. O., Damasceno, N. R. T., Neto, A. M. F., França, C. N., Caixeta, A. M., Bianco, H. T., Póvoa, R., Moreira, F. T., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01559-w · Cited by 8
Chan, D. C., Ying, Q., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000795 · Cited by 6
“trials have consistently demonstrated that PCSK9 mAbs, such as evolocumab and alirocumab, can effectively lower plasma LDL-cholesterol and reduce the incidence of ASCVD outcomes [33,34].”
BackgroundLiu, J., Fan, F., Luo, X., Ji, W., Liu, Y., Zhang, Y., & Zheng, B. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.758956 · Cited by 7
“Recently, therapies directed against PCSK9 have dramatically decreased LDL-C concentrations and reduced CV events under statin treatment (4).”
BackgroundLevintow, S. N., Reading, S. R., Noshad, S., Mayer, S. E., Wiener, C., Eledath, B., Exter, J., & Brookhart, M. A. (2022) · Clinical Epidemiology · doi:10.2147/clep.s361258 · Cited by 7
“Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), in particular, are a class of non-statin LLT comprising monoclonal antibodies that function to block the PCSK9 protein, and, in clinical trials, adding PCSK9i to a statin led to greater lowering of LDL-C than statin monotherapy and reduced the risks of…”
BackgroundMorieri, M. L., Pipino, C., & Doria, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091402 · Cited by 7
“PCSK9i are very effective and well-tolerated LDL cholesterol-reducing drugs with proven cardiovascular efficacy among subjects at very high cardiovascular risk [24,25].”
BackgroundLeatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 7
Self-citationMusumeci, G., Annibali, G., & Delnevo, F. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad086 · Cited by 6
Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
Fruchart, J., Santos, R. D., Yamashita, S., Libby, P., Fruchart, J., Santos, R. D., Yamashita, S., Aikawa, M., Libby, P., Plutzky, J., et al. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.034 · Cited by 6
Modulation of cholesterol efflux capacity in patients with myocardial infarction
Silvain, J., Kernéis, M., Guérin, M., & Montalescot, G. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000677 · Cited by 6
Shingai, Y., Kimura, N., Doijiri, R., Takahashi, K., Yokosawa, M., Kanoke, A., Kikuchi, T., Sugawara, T., & Tominaga, T. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.10.095 · Cited by 7
Vrablı́k, M., Pitha, J. V., Blaha, V., Cífková, R., Freiberger, T., Karásek, D., Kraml, P. J., Rosolová, H., Soška, V., Štulc, T., et al. (2020) · Cor et Vasa · doi:10.33678/cor.2020.024 · Cited by 6
Recent dyslipidemia guidelines for patients with diabetes mellitus
Rhee, E. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00100 · Cited by 7
“In the latest PCSK9 inhibitor studies, such as the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) and ODYSSEY, the cardiovascular disease prevention effect of this drug was demonstrated in patients already on statins, as it additionally lowered the LDL-C level a…”
MethodShould We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
Orringer, C. E., Tokgözoğlu, L. S., Maki, K. C., Ray, K. K., Saseen, J. J., & Catapano, A. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018189 · Cited by 8
Bempedoic acid: Review of a novel therapy in lipid management
Delevry, D., & Gupta, E. K. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa352 · Cited by 8
Ashfaq, T., Shahzad, F., Ishaq, A., Naseem, S., & Saleem, F. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93995 · Cited by 7
Guijarro, C., Civeira, F., López‐Miranda, J., Masana, L., Pedro‐Botet, J., Pintó, X., Valdivielso, P., & Mostaza, J. M. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.07.002 · Cited by 6
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.11.004 · Cited by 7
PCSK9 inhibitors: what we know, what we should have understood, and what is to come
Sabatine, M. S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz514 · Cited by 7
Current Management and Therapy of Severe Aortic Stenosis and Future Perspective
Takeji, Y., Tada, H., Taniguchi, T., Sakata, K., Kitai, T., Shirai, S., & Takamura, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22023 · Cited by 7
Gurevitz, C., Zadok, O. I. B., Leshem‐Lev, D., Hodeda, L., Rotholz, A., Kornowski, R., & Eisen, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100896 · Cited by 6
“Inclisiran: Early LDL-C target achievement in a real-life population”
Briani, F., Bagli, M., Venturi, G., Bacchion, F., & Mugnolo, A. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.01.001 · Cited by 7
“The potential clinical effectiveness of rapidly lowering LDL cholesterol following an acute clinical event, e.g. an acute coronary syndrome, is supported by several studies, including the IMPROVE-IT study and more recently, the FUORIER and ODYSSEY OUTCOMES trials [19 – 21].”
D’Andrea, D., Capone, V., Bellis, A., Castaldo, R., Franzese, M., Carpinella, G., Furbatto, F., Rocca, F. L., Marsico, F., Marfella, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092992 · Cited by 9
“The choice of an aggressive pharmacological approach to decrease the low-density lipoprotein cholesterol (LDL-C) values in patients with recent ACS (1 to 12 months earlier) has allowed us to reduce the incidence of major adverse cardiovascular events (MACEs) [2,3].”
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis
Cleto, A. S., Schirlo, J. M., Machozeki, J., & Martins, C. M. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x357542250526072430 · Cited by 5
Labinaz, A., Yao, R., Hosseini, F., Turgeon, R. D., Marchand, M., Brunham, L. R., Hawkins, N. M., Wong, G. C., Mancini, G. B. J., & Fordyce, C. B. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.021 · Cited by 7
“19,20 Associated with these decreases in LDL levels, an accompanying 6%-16% relative risk reduction in MACE has been reported with the use of LLTs. 18,20,21 22-25 Current Canadian Guideline Recommendations for Dyslipidemia Management Following an ACS Several Canadian guidelines outline…”
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Kao, G., Chen, C., Zhang, Y., Xu, Y., & Xu, G. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05070-3 · Cited by 10
“For alirocumab, the pooled HR was 0.84 (95% CI: 0.75–0.94; I² = 18%), consistent with findings from large-scale trials such as ODYSSEY OUTCOMES [19] and PACMAN-AMI [22].”
InfluentialGargiulo, P., Ray, K. K., & Filardi, P. P. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf615 · Cited by 6
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 6
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Razavi, A. C., & Shapiro, M. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101314 · Cited by 11
“…led to a 1.6 % absolute risk reduction (NNT = 63) over 2.8 years among nearly 19,000 individuals who had experienced acute coronary syndrome within the last 12 months and had inadequately controlled cholesterol on statins (LDL-C ≥ 70, non-HDL-C ≥ 100, or apolipoprotein-B [ApoB] ≥ 80 mg/dL) [8].”
InfluentialReijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M. J., Trompet, S., Bhatt, D. L., Bittner, V., Díaz, R., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322336 · Cited by 7
Self-citationDrexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
“83 In ODYSSEY OUTCOMES, LDL-cholesterol was reduced by ∼ 60% 79 and in patients with diabetes alirocumab showed a greater absolute risk reduction that was attributable to their higher baseline risk (2.3%).”
InfluentialTanaka, A., Oyama, K., Yakushiji, Y., Natsuaki, M., Mizuno, A., Saito, Y., Matsumoto, S., Yamagami, H., Kunieda, T., Shibata, S., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65908 · Cited by 7
Ray, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 6
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

